Research programme: small molecule therapeutics - Daiichi Sankyo
Alternative Names: D11-5908Latest Information Update: 16 Jul 2016
At a glance
- Originator Daiichi Sankyo Company
- Class Small molecules
- Mechanism of Action Very late antigen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)
- 21 Jan 2009 Preclinical trials in Acute myeloid leukaemia in USA (PO)